Dupilumab Development Program In addition to the currently approved indications, Regeneron and Sanofi are also studying dupilumab in a broad range of clinical development programs for diseases driven by allergic and other type 2 inflammation, including pediatric asthma (6 to 11 years of age, Phase 3), pediatric atopic dermatitis (6 months to 5 years of age, Phase 2/3), eosinophilic esophagitis (Phase 3), chronic obstructive pulmonary disease (Phase 3), bullous pemphigoid (Phase 3), prurigo nodularis (Phase 3), chronic spontaneous urticaria (Phase 3), and food and environmental allergies (Phase 2)
But the very qualities that make GLP-1s such powerful tools for weight loss also make them potentially dangerous for those who struggle to adequately feed themselves
C 14 H 24 N 6 O 4 (free tripeptide) Molecular Weight: 402.91 g/mol (complex)
Do you think this could revolutionize treatment options for obesity and osteoarthritis
What Conditions Can Tesamorelin / CJC-1295 / Ipamorelin Treat
